Physician

Jay Henderson Warrick, M.D.

According to 2025 Medicare claims, Jay Warrick, M.D. (NPI: 1326083015) practices rheumatology in the Knoxville, TN market, with the plurality of this provider's patient population coming from Knox, TN. This provider's primary affiliated billing organization is RHEUMATOLOGY CONSULTANTS, PLLC (NPI: 1922143429; TIN: 621064119) and primary practice location at 37909-1907.

Warrick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 300 traditional Medicare patients, billed 91,593 HCPCS/CPT codes, and received $1,197,823 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,775 prescription claims across 413 beneficiaries totaling $2,476,515 in drug costs, led by Rinvoq (Upadacitinib). 2019 DME data shows 12 claims. Open Payments data shows 121 records totaling $2,167. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $673,482 to $1,197,823. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,175,870 to $2,476,515. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	313	44,447	$673,482
2016	335	40,080	$800,559
2017	332	47,584	$1,020,143
2018	309	48,775	$1,073,847
2019	308	60,699	$1,241,950
2020	294	67,951	$1,174,273
2021	269	48,772	$881,601
2022	283	75,012	$1,030,674
2023	303	73,898	$1,137,157
2024	300	91,593	$1,197,823

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	483	4,697	$1,175,870
2016	427	4,589	$1,247,653
2017	371	3,904	$1,053,798
2018	381	3,821	$1,653,385
2019	393	3,576	$1,790,908
2020	375	3,712	$1,983,054
2021	344	3,371	$2,120,103
2022	384	3,490	$2,395,450
2023	418	3,622	$2,313,035
2024	413	3,775	$2,476,515

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$1,354
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	228	429	$80
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	213	340	$12
36415	Insertion of needle into vein for collection of blood sample	144	318	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	171	410	$7
85651	Red blood cell sedimentation rate, to detect inflammation, non-automated	156	293	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	67	2,250	$502,872
Humira(Cf) Pen	Adalimumab	18	784	$190,585
Enbrel Sureclick	Etanercept	24	672	$176,784
Xeljanz Xr	Tofacitinib Citrate	23	870	$170,127
Taltz Autoinjector	Ixekizumab	23	644	$153,782

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	121	$2,167	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jay Henderson Warrick, M.D.?

Tedicare shows public-source Medicare data for Jay Henderson Warrick, M.D. (NPI 1326083015), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay Henderson Warrick, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jay Henderson Warrick, M.D.?

Jay Henderson Warrick, M.D. is linked to RHEUMATOLOGY CONSULTANTS, PLLC (billing NPI 1922143429) in the available physician profile data.

Does Jay Henderson Warrick, M.D. have Open Payments data?

Jay Henderson Warrick, M.D. has 121 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.